Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob P Laubach

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2015
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New HorizonJacob P Laubach, Paul G Richardson
Nature Reviews. Clinical Oncology|September 30, 2009
Hematology: Thalidomide maintenance in multiple myelomaJacob P Laubach, Paul G Richardson, Kenneth C Anderson
Hematology. American Society of Hematology. Education Program|December 17, 2009
Finding the right academic jobIrene M Ghobrial, Jacob P Laubach, Robert J Soiffer
Medical Oncology (Northwood, London, England)|February 20, 2010
The evolution and impact of therapy in multiple myelomaJacob P Laubach, Paul G Richardson, Kenneth C Anderson
Dermatology Online Journal|March 18, 2015
Scleromyxedema with histology resembling granuloma annulareSamyukta Mullangi, Scott R Granter, Jacob P Laubach, et al.
British Journal of Haematology|May 12, 2018
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myelomaCindy Varga, Jacob P Laubach, Kenneth C Anderson, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Practical Considerations for Antibodies in MyelomaJacob P Laubach, Niels van de Donk, Faith E Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2015
Panobinostat for the Treatment of Multiple MyelomaJacob P Laubach, Philippe Moreau, Jesús F San-Miguel, et al.
Hematology. American Society of Hematology. Education Program|February 20, 2015
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?Paul G Richardson, Jacob P Laubach, Nikhil C Munshi, et al.
Expert Opinion on Investigational Drugs|February 22, 2014
Daratumumab granted breakthrough drug statusJacob P Laubach, Yu-Tzu Tai, Paul G Richardson, et al.
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2015
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New HorizonJacob P Laubach, Paul G Richardson
Nature Reviews. Clinical Oncology|September 30, 2009
Hematology: Thalidomide maintenance in multiple myelomaJacob P Laubach, Paul G Richardson, Kenneth C Anderson
Hematology. American Society of Hematology. Education Program|December 17, 2009
Finding the right academic jobIrene M Ghobrial, Jacob P Laubach, Robert J Soiffer
Medical Oncology (Northwood, London, England)|February 20, 2010
The evolution and impact of therapy in multiple myelomaJacob P Laubach, Paul G Richardson, Kenneth C Anderson
Dermatology Online Journal|March 18, 2015
Scleromyxedema with histology resembling granuloma annulareSamyukta Mullangi, Scott R Granter, Jacob P Laubach, et al.
British Journal of Haematology|May 12, 2018
Investigational agents in immunotherapy: a new horizon for the treatment of multiple myelomaCindy Varga, Jacob P Laubach, Kenneth C Anderson, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Practical Considerations for Antibodies in MyelomaJacob P Laubach, Niels van de Donk, Faith E Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2015
Panobinostat for the Treatment of Multiple MyelomaJacob P Laubach, Philippe Moreau, Jesús F San-Miguel, et al.
Hematology. American Society of Hematology. Education Program|February 20, 2015
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?Paul G Richardson, Jacob P Laubach, Nikhil C Munshi, et al.
Expert Opinion on Investigational Drugs|February 22, 2014
Daratumumab granted breakthrough drug statusJacob P Laubach, Yu-Tzu Tai, Paul G Richardson, et al.
Pageof 12